Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N07XX14
|
| gptkbp:brand |
gptkb:Givlaari
|
| gptkbp:CASNumber |
1446321-46-5
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:drugClass |
small interfering RNA
RNA interference therapeutic |
| gptkbp:form |
solution for injection
|
| gptkbp:hasMolecularFormula |
C204H267F94N61O65P19S19
|
| https://www.w3.org/2000/01/rdf-schema#label |
Givosiran
|
| gptkbp:indication |
treatment of acute hepatic porphyria in adults
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
aminolevulinate synthase 1 (ALAS1) inhibitor
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
nausea
fatigue injection site reaction renal impairment increased liver enzymes |
| gptkbp:target |
ALAS1 mRNA
|
| gptkbp:UNII |
6Z1Y2V4S2E
|
| gptkbp:usedFor |
gptkb:acute_hepatic_porphyria
|
| gptkbp:bfsParent |
gptkb:small_interfering_RNA_(siRNA)
gptkb:Servier_Pharmaceuticals |
| gptkbp:bfsLayer |
7
|